Erythropoietin and the hypoxic brain - PubMed (original) (raw)
Review
. 2004 Aug;207(Pt 18):3233-42.
doi: 10.1242/jeb.01049.
Affiliations
- PMID: 15299044
- DOI: 10.1242/jeb.01049
Review
Erythropoietin and the hypoxic brain
Hugo H Marti. J Exp Biol. 2004 Aug.
Abstract
Normal tissue function in mammals depends on adequate supply of oxygen through blood vessels. A discrepancy between oxygen supply and consumption (hypoxia) induces a variety of specific adaptation mechanisms at the cellular, local and systemic level. These mechanisms are in part governed by the activation of hypoxia-inducible transcription factors (HIF-1, HIF-2), which in turn modulate expression of hypoxically regulated genes such as those encoding vascular endothelial growth factor (VEGF) and erythropoietin (EPO). EPO is a glycoprotein that is produced mainly by interstitial fibroblasts in the kidneys of the adult and in hepatocytes in the foetus. Released into the circulation, EPO makes its way to the bone marrow, where it regulates red cell production by preventing apoptosis of erythroid progenitor cells. Recently, EPO has emerged as a multifunctional growth factor that plays a significant role in the nervous system. Both EPO and its receptor are expressed throughout the brain in glial cells, neurones and endothelial cells. Hypoxia and ischaemia have been recognised as important driving forces of EPO expression in the brain. EPO has potent neuroprotective properties in vivo and in vitro and appears to act in a dual way by directly protecting neurones from ischaemic damage and by stimulating endothelial cells and thus supporting the angiogenic effect of VEGF in the nervous system. Thus, hypoxia-induced gene products such as VEGF and EPO might be part of a self-regulated physiological protection mechanism to prevent neuronal injury, especially under conditions of chronically reduced blood flow (chronic ischaemia). In this review, I will briefly summarize the recent findings on the molecular mechanisms of hypoxia-regulated EPO expression in general and give an overview of its expression in the central nervous system, its action as a growth factor with non-haematopoietic functions and its potential clinical relevance in various brain pathologies.
Similar articles
- Cellular oxygen sensing need in CNS function: physiological and pathological implications.
Acker T, Acker H. Acker T, et al. J Exp Biol. 2004 Aug;207(Pt 18):3171-88. doi: 10.1242/jeb.01075. J Exp Biol. 2004. PMID: 15299039 Review. - The role and regulation of hypoxia-inducible factor-1alpha expression in brain development and neonatal hypoxic-ischemic brain injury.
Fan X, Heijnen CJ, van der Kooij MA, Groenendaal F, van Bel F. Fan X, et al. Brain Res Rev. 2009 Dec 11;62(1):99-108. doi: 10.1016/j.brainresrev.2009.09.006. Epub 2009 Sep 25. Brain Res Rev. 2009. PMID: 19786048 Review. - Expression of the gene encoding the pro-apoptotic BNIP3 protein and stimulation of hypoxia-inducible factor-1alpha (HIF-1alpha) protein following focal cerebral ischemia in rats.
Althaus J, Bernaudin M, Petit E, Toutain J, Touzani O, Rami A. Althaus J, et al. Neurochem Int. 2006 Jun;48(8):687-95. doi: 10.1016/j.neuint.2005.12.008. Epub 2006 Feb 7. Neurochem Int. 2006. PMID: 16464515 - Suppression of erythropoietin gene expression by cadmium depends on inhibition of HIF-1, not stimulation of GATA-2.
Obara N, Imagawa S, Nakano Y, Suzuki N, Yamamoto M, Nagasawa T. Obara N, et al. Arch Toxicol. 2003 May;77(5):267-73. doi: 10.1007/s00204-003-0444-0. Epub 2003 Mar 7. Arch Toxicol. 2003. PMID: 12734640 - Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators.
Déry MA, Michaud MD, Richard DE. Déry MA, et al. Int J Biochem Cell Biol. 2005 Mar;37(3):535-40. doi: 10.1016/j.biocel.2004.08.012. Int J Biochem Cell Biol. 2005. PMID: 15618010 Review.
Cited by
- Chronic Administration of Recombinant Human Erythropoietin Induces Angiogenesis in Healthy Mouse Brain.
Pagonopoulou O, Papadatou V, Tologkos S, Efthimiadou A, Maria L. Pagonopoulou O, et al. Cureus. 2024 Sep 1;16(9):e68362. doi: 10.7759/cureus.68362. eCollection 2024 Sep. Cureus. 2024. PMID: 39355466 Free PMC article. - Emerging therapeutic strategies in hypoxic-ischemic encephalopathy: a focus on cognitive outcomes.
Marques KL, Rodrigues V, Balduci CTN, Montes GC, Barradas PC, Cunha-Rodrigues MC. Marques KL, et al. Front Pharmacol. 2024 Feb 26;15:1347529. doi: 10.3389/fphar.2024.1347529. eCollection 2024. Front Pharmacol. 2024. PMID: 38469401 Free PMC article. Review. - Beneficial Effect of Erythropoietin on Ameliorating Propionic Acid-Induced Autistic-Like Features in Young Rats.
A Hosny S, M Abdelmenem A, Azouz T, S Kamar S, M ShamsEldeen A, A El-Shafei A. A Hosny S, et al. Acta Histochem Cytochem. 2023 Oct 31;56(5):77-86. doi: 10.1267/ahc.23-00027. Epub 2023 Oct 4. Acta Histochem Cytochem. 2023. PMID: 37970239 Free PMC article. - Recombinant Erythropoietin Induces Oligodendrocyte Progenitor Cell Proliferation After Traumatic Brain Injury and Delayed Hypoxemia.
Shumilov K, Xiao S, Ni A, Celorrio M, Friess SH. Shumilov K, et al. Neurotherapeutics. 2023 Oct;20(6):1859-1874. doi: 10.1007/s13311-023-01443-8. Epub 2023 Sep 28. Neurotherapeutics. 2023. PMID: 37768487 Free PMC article. - Exploiting moderate hypoxia to benefit patients with brain disease: Molecular mechanisms and translational research in progress.
Ehrenreich H, Gassmann M, Poustka L, Burtscher M, Hammermann P, Sirén AL, Nave KA, Miskowiak K. Ehrenreich H, et al. Neuroprotection. 2023 Sep;1(1):9-19. doi: 10.1002/nep3.15. Epub 2023 Feb 21. Neuroprotection. 2023. PMID: 37671067 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials